Public Employees Retirement Association of Colorado Trims Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Public Employees Retirement Association of Colorado lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,875 shares of the biopharmaceutical company’s stock after selling 522 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Alnylam Pharmaceuticals were worth $2,074,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Bellevue Group AG raised its holdings in Alnylam Pharmaceuticals by 3.7% in the 1st quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock worth $137,238,000 after purchasing an additional 32,966 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after buying an additional 201,784 shares during the period. BOKF NA raised its stake in Alnylam Pharmaceuticals by 23.9% in the first quarter. BOKF NA now owns 6,712 shares of the biopharmaceutical company’s stock worth $1,029,000 after buying an additional 1,295 shares in the last quarter. Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals in the first quarter worth about $30,000. Finally, Canada Pension Plan Investment Board boosted its position in Alnylam Pharmaceuticals by 12.7% during the 1st quarter. Canada Pension Plan Investment Board now owns 273,790 shares of the biopharmaceutical company’s stock valued at $40,918,000 after acquiring an additional 30,792 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.6 %

Shares of ALNY stock opened at $236.28 on Tuesday. The company has a 50 day moving average price of $200.71 and a 200-day moving average price of $172.70. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $263.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The company’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period last year, the firm posted ($1.40) EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current year.

Analysts Set New Price Targets

ALNY has been the subject of several research reports. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 25th. HC Wainwright reissued a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Chardan Capital reaffirmed a “buy” rating and issued a $225.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Citigroup increased their price target on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, UBS Group upped their price objective on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a report on Friday, June 28th. Eight research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.73.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the transaction, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 7,093 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,168,101. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,450 shares of company stock worth $15,287,984. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.